User:Ann Taylor/GLP-1 agonists: Difference between revisions
Jump to navigation
Jump to search
GLP-1 agonists
References
Ann Taylor (talk | contribs) No edit summary |
Ann Taylor (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
<scene name='10/1043704/Glp-1_peptide/1'>Glucagon-like peptide agonists</scene> (GLP) are used to treat type 2 diabetes and obesity <ref>PMID:38639549</ref>. They GLP-1 agonists bind to the GLP receptor. | <scene name='10/1043704/Glp-1_peptide/1'>Glucagon-like peptide agonists</scene> (GLP) are used to treat type 2 diabetes and obesity <ref>PMID:38639549</ref>. They GLP-1 agonists bind to the GLP receptor. | ||
The GLP receptor is a G-protein coupled receptor. Its secondary structure is highlighted in <scene name='10/1043704/Glpr_secondary/1'>this view</scene>. The hydrophobic residues are shown in grey and the polar residues are shown in magenta in <scene name='10/1043704/Glpr_hydrophobic_hydrophilic/1'>this view</scene>. | |||
</StructureSection> | </StructureSection> | ||
Revision as of 23:12, 5 December 2024
GLP-1 agonistsGLP-1 agonists
(GLP) are used to treat type 2 diabetes and obesity [1]. They GLP-1 agonists bind to the GLP receptor. The GLP receptor is a G-protein coupled receptor. Its secondary structure is highlighted in . The hydrophobic residues are shown in grey and the polar residues are shown in magenta in .
|
| ||||||||||
ReferencesReferences
- ↑ Drake T, Landsteiner A, Langsetmo L, MacDonald R, Anthony M, Kalinowski C, Ullman K, Billington CJ, Kaka A, Sultan S, Wilt TJ. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2024 Apr 19. PMID:38639549 doi:10.7326/M23-1490